PMID: 9529032Apr 7, 1998Paper

A phase II trial of paclitaxel in refractory germ cell tumors

Cancer
A B SandlerB J Roth

Abstract

A significant percentage of patients with refractory germ cell tumors will not respond to standard salvage regimens. Thus there is a need for new active agents. Paclitaxel has demonstrated activity against a variety of solid tumors in both laboratory and clinical studies. Eighteen patients with refractory germ cell tumors who failed initial cisplatin-based chemotherapy and a maximum of 2 salvage regimens were enrolled into a Phase II trial of paclitaxel at a dose of 170 mg/m2 by intravenous infusion over 24 hours every 21 days without growth factor support. The median age of the patients was 32.5 years (range, 18-49 years). The testis was the primary site of tumor for 13 patients (72%) and the tumor was extragonadal in 5 patients (28%). Six patients (33%) were late recurrences. Twelve patients (67%) had > or = 2 metastatic sites. The median number of previous chemotherapy cycles was six (range, four to nine). Three patients (17%) previously had undergone autologous bone marrow transplantation. Two patients (11%) responded to paclitaxel. Major toxicities were Grade 3-4 neutropenia (55% of patients) and Grade 3-4 neurotoxicity (2 patients). Neutropenic fever occurred in 3 patients (17%). Paclitaxel demonstrated minimal activity i...Continue Reading

References

Feb 22, 1979·Nature·P B SchiffS B Horwitz
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R NicholsL H Einhorn
Jun 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F OzolsR C Young
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H EinhornF A Greco
May 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·P B Schiff, S B Horwitz
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerP Fischer
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BanielL H Einhorn
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A EisenhauerN Colombo
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S B SaxmanL H Einhorn
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B R MurphyL H Einhorn
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F BajorinP Sogani
Jan 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerH J Schmoll
Sep 1, 1995·Urologic Oncology·A NazarioC J Logothetis

❮ Previous
Next ❯

Citations

Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C BokemeyerL Kanz
Jun 5, 2003·Current Opinion in Oncology·Beth A Hellerstedt, Kenneth J Pienta
Feb 8, 2006·Cancer·Christian KollmannsbergerCarsten Bokemeyer
Dec 22, 1999·International Journal of Cancer. Journal International Du Cancer·C BokemeyerL Kanz
Mar 10, 2005·Der Urologe. Ausg. A·M KuczykJ Beyer
Mar 9, 2018·Expert Review of Anticancer Therapy·Christoph OingCarsten Bokemeyer
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H EinhornS D Williams
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P PorcuL H Einhorn
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lawrence H EinhornStephen D Williams
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pablo M BedanoLawrence H Einhorn
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Apr 26, 2002·International Journal of Urology : Official Journal of the Japanese Urological Association·Tsuneharu Miki, Masahiro Nakao
Dec 10, 1999·Seminars in Surgical Oncology·C R Nichols
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stuart HintonGeorge Wilding
Apr 4, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C TheodoreA Flechon
Aug 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F HoneckerA Horwich

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.